Elixir grants Novartis an acquisition option
21 May 2009
Sukaina Virji
Please Login to read the full article.
21 May 2009
Sukaina Virji
sukaina.virji@informa.com
Elixir Pharmaceuticals has granted Novartis an exclusive option to acquire the US company following the completion of a Phase IIa study of its lead oral ghrelin antagonist, which is currently in late preclinical development in the US for the treatment of type 2 diabetes.
Elixir hopes to file...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Actos suspension could shake up a market already in transition
- Xoma to use acquired Servier hypertension drug to establish a US commercial operation
- Comparator choice scuppers BI/Lilly's Trajenta assessment in Germany
- Miragen reels in $45 million up front in microRNA deal with Servier
COMMENT
Other Informa Comment
FEATURES
- DKSH highlights one-stop benefits as it builds Asia market expansion services
- Merck BioVentures: where biosimilars make a difference
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
